Cargando…

Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma

PURPOSE: This study aimed to develop a radiomics signature for the preoperative prognosis prediction of isocitrate dehydrogenase (IDH)-wild-type glioblastoma (GBM) patients and to provide personalized assistance in the clinical decision-making for different patients. MATERIALS AND METHODS: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shouchao, Xiao, Feng, Sun, Wenbo, Yang, Chao, Ma, Chao, Huang, Yong, Xu, Dan, Li, Lanqing, Chen, Jun, Li, Huan, Xu, Haibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833841/ https://www.ncbi.nlm.nih.gov/pubmed/35153659 http://dx.doi.org/10.3389/fnins.2021.791776

Ejemplares similares

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy
por: Zhao, Chao, et al.
Publicado: (2021)

Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults
por: King-Stephens, David
Publicado: (2022)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns
por: Lo, Chung-Ming, et al.
Publicado: (2020)

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
por: Ehret, Felix, et al.
Publicado: (2023)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas
por: Liu, Yan, et al.
Publicado: (2023)

A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis
por: Conte, Brianna, et al.
Publicado: (2022)

A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma
por: Wang, Lei-Ming, et al.
Publicado: (2021)

The T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase wild-type A case report
por: Nishimura, Shunsuke, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
por: Oh, Sejin, et al.
Publicado: (2020)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas
por: Wu, Shuang, et al.
Publicado: (2019)

Preoperative Magnetic Resonance Imaging Radiomics for Predicting Early Recurrence of Glioblastoma
por: Wang, Jing, et al.
Publicado: (2021)

IMG-21. PROSPECTIVE PREOPERATIVE DETERMINATION OF ISOCITRATE DEHYDROGENASE MUTATION IN GLIOMAS USING SPECTRAL EDITING MAGNETIC RESONANCE SPECTROSCOPY
por: Nguyen, Thanh, et al.
Publicado: (2020)

Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma
por: Koh, Sabrina P., et al.
Publicado: (2017)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Clinical implications of hypoxia-inducible factor-1α and caveolin-1 overexpression in isocitrate dehydrogenase-wild type glioblastoma multiforme
por: Chen, Wenli, et al.
Publicado: (2019)

Favorable prognostic impact of phosphatase and tensin homolog alterations in wild-type isocitrate dehydrogenase and telomerase reverse transcriptase promoter glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2023)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms
por: QI, SONGTAO, et al.
Publicado: (2014)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
por: Polivka, J., et al.
Publicado: (2014)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas
por: Sahu, Arpita, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide
por: Clavreul, Anne, et al.
Publicado: (2021)

Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme
por: Cai, Xiaomin, et al.
Publicado: (2022)

Assessment of Isocitrate Dehydrogenase 1 Genotype and Cell Proliferation in Gliomas Using Multiple Diffusion Magnetic Resonance Imaging
por: Xie, Yan, et al.
Publicado: (2021)

Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas
por: Wang, Pu, et al.
Publicado: (2012)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance
por: He, Qiwei, et al.
Publicado: (2022)

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma
por: Li, Xianqi, et al.
Publicado: (2022)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

U3 snoRNA‐mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild‐type glioblastoma cells
por: Dong, Weiwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nr9mqnkp2u3ndl20iivu75fsd4